AMCP Comments on PREVENT HPV Cancers Act
AMCP Submits Comments on MCIT Rule
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare & Medicaid Services (CMS) for the opportunity to provide comments in response to its interim final rule with comment (IFC) period titled “Medicare Program; Medicare Coverage of Innovative Technology (MCIT) and Definition of “Reasonable and Necessary”; Delay of Effective Date; Public Comment Period (CMS-3372-IFC)” published on March 17, 2021. We appreciate the opportunity to leverage our members’ expertise in offering feedback on this rule.
Related
On September 9, AMCP submitted comments praising CMS’s proposal to cover Digital Mental Health Treatment devices (DMHTs) under Medicare Part B. AMCP urges CMS to use its authority to cover all FDA-cleared, prescription only digital health products and develop appropriate coding and payment methodologies to promote adoption of these innovative technologies.
SB 966, California's PBM reform bill, could reshape pharmacy benefit manager regulation if signed into law. Governor Newsom’s decision is expected by September 30.
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
